In Canada, carcinoma In Situ is managed by oncologists. Carcinoma in situ (CIS) is the earliest histologic stage of cancer, defined by malignant cells confined to the epithelium without breach of the basement membrane that separates them from underlying tissue and blood vessels. Because invasion has not occurred, CIS cannot metastasize and has a 5-year survival above 95% across most sites with appropriate treatment.

Carcinoma in situ (ICD-10: D00-D09) is a histopathologic diagnosis defined by malignant epithelial cells that show the full cytologic and architectural features of cancer but remain confined to the epithelium of origin, without breaching the underlying basement membrane. Because invasion of stroma is required for access to blood vessels and lymphatics, CIS has no metastatic potential at the time of diagnosis. The 8th edition AJCC staging classifies CIS as stage 0 disease and assigns it a Tis (T-in-situ) designation across most cancer sites. The concept is unified across anatomy: ductal carcinoma in situ (DCIS) and lobular carcinoma in situ (LCIS) in the breast; cervical intraepithelial neoplasia grade 3 (CIN3) — by current terminology high-grade squamous intraepithelial lesion (HSIL) at the cervix; Bowen disease (squamous cell carcinoma in situ) in the skin; CIS of bladder urothelium; high-grade dysplasia of esophagus, stomach, and colon (which the WHO 2019 classification now formally equates with carcinoma in situ); and CIS of the larynx, vulva, anus, prostate, and other organs.

The key symptoms of Carcinoma In Situ are: Most carcinomas in situ are asymptomatic and detected only by imaging or cytologic screening — this is the dominant clinical fact about the diagnosis., DCIS may present as a palpable breast lump or new nipple discharge in 10-20% of cases, but most are detected as microcalcifications on routine mammography., Cervical intraepithelial neoplasia is almost always asymptomatic and detected on cervical screening (cytology, HPV testing, or both); abnormal bleeding suggests invasive disease., Bowen disease appears as a slowly enlarging, red, scaly, well-defined patch or plaque on sun-exposed skin, often mistaken for eczema or psoriasis for months., Bladder carcinoma in situ may present with painful urination, urinary frequency, and microscopic or visible hematuria, sometimes resembling refractory urinary tract infection., High-grade dysplasia in Barrett esophagus is usually asymptomatic and detected during surveillance endoscopy in patients with known long-standing gastroesophageal reflux disease., Anal and vulvar intraepithelial neoplasia can cause itching, burning, or a visible lesion noted by patient or clinician..

Diagnosis of carcinoma in situ is histopathologic, requiring tissue biopsy with confirmation that malignant epithelial cells are present without invasion through the basement membrane. The diagnostic pathway varies by site, but in every case starts with screening detection or symptom-driven evaluation followed by targeted biopsy. For DCIS, screening mammography identifies clustered microcalcifications, branching microcalcifications, or rarely a mass; stereotactic core needle biopsy provides tissue. Pathology characterizes grade (low, intermediate, high), architectural pattern (cribriform, micropapillary, solid, comedo), estrogen and progesterone receptor status, and HER2. For cervical intraepithelial neoplasia, cervical cytology (Pap test) and high-risk HPV testing are the screening tools; an abnormal screen triggers colposcopy with directed biopsy. The 2019 ASCCP risk-based management guidelines now stratify treatment by composite risk of CIN3+ rather than by single test result, reducing both overtreatment and undertreatment. For Bowen disease, dermatoscopic examination of a persistent scaly plaque is followed by shave or punch biopsy demonstrating full-thickness atypia of keratinocytes. For bladder CIS, urinary cytology has high sensitivity for high-grade urothelial lesions, and white-light cystoscopy supplemented by blue-light fluorescence cystoscopy with hexaminolevulinate improves detection of flat lesions. Biopsy of suspicious areas and random bladder mapping biopsies confirm the diagnosis. For Barrett esophagus, surveillance endoscopy with four-quadrant biopsies every 2 cm of Barrett segment detects high-grade dysplasia. Two expert gastrointestinal pathologists should confirm the diagnosis given the implications for treatment. Across all sites, immunohistochemistry and molecular profiling are increasingly used to predict progression risk and guide treatment intensity.
Prognosis for carcinoma in situ is excellent overall. 5-year survival exceeds 95% across virtually all sites with appropriate treatment, reflecting the absence of metastatic potential at diagnosis. For DCIS, 10-year breast-cancer-specific mortality is under 3%; most recurrences are local rather than systemic, and half of local recurrences are invasive disease that drive longer-term mortality risk. For CIN3, cure rates exceed 90% with excisional treatment, and progression to invasive cervical cancer is rare during surveillance. For Bowen disease, cure rates with all standard treatments are 75-95%; rare progression to invasive squamous cell carcinoma occurs in 3-5% over years. For bladder CIS, complete response to BCG therapy is achieved in 65-75% at 3 months, with progression to muscle-invasive disease in approximately 15-20% over 5 years. For high-grade dysplasia in Barrett esophagus, endoscopic therapy achieves complete eradication of intestinal metaplasia in 80-90% with low recurrence on continued surveillance. Long-term prognosis depends most on adherence to surveillance, control of underlying drivers (HPV, smoking, reflux, sun exposure), and timely treatment of recurrences. Overdiagnosis is a recognized concern — particularly for low-grade DCIS, where many lesions may never progress; this is driving the growth of active surveillance research.
Carcinoma in situ should be managed by a site-appropriate specialist team. DCIS is managed by breast surgeons, medical oncologists, and radiation oncologists. CIN is managed by gynecologic oncologists or colposcopists. Bowen disease and other cutaneous CIS are managed by dermatologists and dermatologic surgeons. Bladder CIS is managed by urologic oncologists. Barrett high-grade dysplasia is managed by therapeutic gastroenterologists. Multidisciplinary tumor boards review complex cases. Genetic counseling is offered to patients with personal or family histories suggesting hereditary syndromes.
Find specialists →Recovery after CIS treatment varies by procedure: lumpectomy with radiation involves 4-6 weeks of daily radiation followed by full recovery over 8-12 weeks; LEEP for CIN3 recovers within 2-4 weeks with minimal bleeding; topical or photodynamic therapy for Bowen disease causes 2-4 weeks of inflammation and crusting with healing over 1-2 months; intravesical BCG induction runs over 6 weeks with maintenance over 1-3 years; endoscopic ablation of Barrett high-grade dysplasia requires multiple sessions 2-3 months apart with full eradication over 6-18 months. Surveillance follow-up continues for years across all sites.
At least 150 minutes of moderate aerobic activity weekly and two sessions of resistance training per American Cancer Society guidelines after CIS diagnosis. Exercise improves cancer-specific and overall survival across multiple CIS sites. After surgical treatment, gradual return to activity over 2-6 weeks depending on the procedure. Walking is appropriate within days of most procedures.
Look for board certification in the relevant specialty, experience with carcinoma in situ specifically, and a multidisciplinary team approach. For DCIS, choose a center with breast-specific imaging, on-site pathology with subspecialty expertise, and access to clinical trials. For CIN, choose colposcopists trained to current ASCCP standards. For Bowen disease, prefer dermatologists with Mohs surgery available. For bladder CIS, prefer urologists with blue-light cystoscopy experience. For Barrett dysplasia, prefer high-volume endoscopists comfortable with endoscopic mucosal resection and radiofrequency ablation.
Medically reviewed by AIHealz Medical Editorial Board · May 13, 2026
Ranked by patient outcomes and specialized experience.
Verifying top specialists in Canada.
Apply as specialist →Specialists who treat Carcinoma In Situ. Get expert guidance and personalized care.